FALCON-HD
Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease
Phase 2/3 study testing SKY-0515 to see whether it can lower harmful huntingtin protein levels.
RecruitingPhase 2 / Phase 3DrugClinicalTrials.govTreatment trial
- EU sites have not started recruiting yet
Recruiting in: Barranquilla, Belo Horizonte, Buenos Aires +12 more (Argentina, Brazil, Canada +6 more)
Sponsor: Skyhawk Therapeutics, Inc.
Preparing a short plain-English summary.